Patent · US Active

Combination drugs of lachnospiraceae bacteria and human immunoglobulin

US12144835B2 · kind B2 · utility

0Cited by

0References

9Claims

0Family size

Assignees

INSTITUTE OF RADIATION MEDICINE CHINESE ACADEMY OF MEDICAL SCIENCES · CN
Institute of Blood Transfusion, Chinese Academy of Medical Sciences · CN
Shanghai RAAS Blood Products Co., Ltd. · CN

Inventors

Ming Cui · Shandong, CN
Zongkui Wang · Sichuan, CN
Changqing Li · Bloomington, US
Jun Xu · Mason, US
Lu Cheng · Taipei, TW

Key dates

Filing date	Jul 11, 2022
Grant date	Nov 19, 2024
Priority date	—
Expiry date	Oct 9, 2042

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K2039/545
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

A combined drug contains Lachnospiraceae bacteria and human immunoglobulin (HIg). HIg has a therapeutic effect on radiation injuries, and the combination of Lachnospiraceae bacteria and HIg can further improve this therapeutic effect. The combination drug can be administered to patients who were undergoing radiotherapy and to people who accidentally receive excessive irradiation.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.